Glowise editorial guide

Semaglutide vs Tirzepatide: What the Direct Weight-Loss Trial Shows

See which doses and people the direct semaglutide and tirzepatide trials studied for weight loss and blood sugar, and what the results mean for your decision.

Portrait of Maya Lee, Glowise Senior GLP-1 Content Editor

Maya Lee

Glowise Senior GLP-1 Content Editor

Published November 19, 20264 min read
Download the Glowise App

Share this guide

Xfin
Two unbranded medication cartons beside a notebook with a comparison table

Tirzepatide produced more weight loss on average than semaglutide in a direct 72-week trial: 20.2% versus 13.7%. That trial compared specific weekly injections in adults with obesity, or overweight with a qualifying condition, without diabetes. If your decision is about blood sugar, a pill, a newer dose, or whether to switch from something that already works for you, the headline leaves a different question to answer.

Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on both GIP and GLP-1 receptors. The mechanisms describe how the drugs work. The randomized comparisons below show what specific regimens did in people.

What did the head-to-head weight trial actually compare?

SURMOUNT-5 assigned 751 adults at random to weekly under-the-skin injections of tirzepatide or semaglutide, alongside lifestyle counseling. Participants qualified through obesity or through overweight with a weight-related condition such as high blood pressure or obstructive sleep apnea. People with diabetes were excluded. Participants and study staff knew which drug they were using.

At 72 weeksTirzepatideSemaglutide
Maximum tolerated weekly injection dose10 or 15 mg1.7 or 2.4 mg
Estimated average loss from starting weight20.2%13.7%

The difference was 6.5 percentage points of starting weight. At a hypothetical starting weight of 200 lb, that difference is about 13 lb. That arithmetic helps put the group averages in familiar units. A person’s response can be higher or lower, and switching medicines hasn’t been shown to give someone the difference between the two averages. The primary analysis accounted for treatment discontinuation. SURMOUNT-5 publication · Trial protocol · Sponsor’s analysis summary

Does the result cover oral Wegovy or the 7.2 mg injection?

Both are in current U.S. labeling, but neither was tested in SURMOUNT-5. So the strongest conclusion is about the weekly injection regimens in the table. If someone quotes the 6.5-point result to compare Zepbound with Wegovy tablets or Wegovy HD, ask which study compared those exact products. A route or dose change may make the practical choice quite different, even when the active ingredient is still semaglutide. Wegovy prescribing information, sections 2–3

What if your goal is to improve blood sugar?

A different direct trial, SURPASS-2, enrolled adults whose type 2 diabetes was inadequately controlled with metformin. It compared weekly injections of tirzepatide 5, 10 or 15 mg against semaglutide 1 mg for 40 weeks, while participants continued metformin. Average HbA1c fell by 2.01, 2.24 and 2.30 percentage points across the three tirzepatide groups, compared with 1.86 with semaglutide. HbA1c reflects average blood sugar over the preceding months. This comparison addresses glucose control at the tested doses. It didn’t test semaglutide 2 mg or establish which medicine fits every diabetes goal, such as reducing kidney or cardiovascular risks. SURPASS-2 original trial · Ozempic injection prescribing information

Brand and form matter when you ask which evidence applies. Wegovy and Zepbound are weight-management brands for semaglutide and tirzepatide, respectively. Ozempic and Mounjaro have type 2 diabetes indications. The U.S. medication list covers each product’s other uses and forms.

When would the evidence change what you ask for?

  • You’re starting obesity treatment without diabetes. The result supports discussing tirzepatide if greater average weight reduction is a priority. Ask about the exact dose and form your clinician is considering and what you’d do if a refill becomes hard to get.
  • Your current prescription helps and you tolerate it. Bring your actual progress and remaining treatment goal. Ask what a change is expected to add and what it might interrupt, such as stable blood sugars, a routine you can follow or access through your plan.
  • You had to stop because of a reaction. Say which product and dose you took, how symptoms affected eating or drinking, and what was happening around the time they started. In SURMOUNT-5 digestive events were common in both groups, mostly mild or moderate and occurring mainly during dose escalation. The study was designed for weight loss and wasn’t powered to pick a safer drug. The direct tolerability comparison explains what stopping rates can tell you. SURMOUNT-5 publication · Sponsor’s safety limitations

If the decision specifically concerns replacing Ozempic with Mounjaro, bring your current dose, last actual dose and other diabetes medicines to the clinician. The Ozempic-to-Mounjaro switching guide covers that conversation. The trial comparisons help set expectations for a particular treatment goal. Your refill, dose and monitoring plan come from the prescriber and pharmacist.

Portrait of Maya Lee, Glowise Senior GLP-1 Content Editor

About the author

Maya Lee

Glowise Senior GLP-1 Content Editor

Maya Lee is a Glowise Health Content Editor. Her guides turn product records, authoritative sources, and everyday organization questions into clear, practical GLP-1 information.

She helps readers ask better questions and keep the details relevant to a care conversation together.

See more Glowise on Google

Add Glowise as a preferred source to find our GLP-1 guides more easily in Google Search.

Glowise library

Bring your GLP-1 routine into one place.

Download the Glowise app to keep medication, meals, hydration, side effects, and progress together.